Medistim ASAFRA:MD1 -2.21%100 Return-on-Tangible-Equity is 42.10% as of Mar. 2026, which is 15% above its 10-year median of 36.57. GuruFocus rates FRA:MD1 with a GF Score™ of 100/100 and a GF Value™ of €23.09 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 760 Medical Devices & Instruments companies, Medistim ASA ranks better than 91.32% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medistim ASA's annualized net income for the quarter that ended in Mar. 2026 was €14.44 Mil. Medistim ASA's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €34.29 Mil. Therefore, Medistim ASA's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 42.10%.
The historical rank and industry rank for Medistim ASA's Return-on-Tangible-Equity or its related term are showing as below:
FRA:MD1'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 28.51 Med: 36.57 Max: 42.77
Current: 42.77
During the past 13 years, Medistim ASA's highest Return-on-Tangible-Equity was 42.77%. The lowest was 28.51%. And the median was 36.57%.
FRA:MD1's Return-on-Tangible-Equity is ranked better than 91.32% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs FRA:MD1: 42.77
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medistim ASA Return-on-Tangible-Equity Related Terms
Medistim ASA Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medistim ASA's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MD1 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Medistim ASA's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medistim ASA's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 42.10% mean?
Medistim ASA (FRA:MD1) has a Return-on-Tangible-Equity of 42.10% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medistim ASA and its competitors. This is 15% above median its historical median of 36.57. Over the past decade, Medistim ASA's Return-on-Tangible-Equity has ranged from 28.51 to 42.77. According to the industry distribution chart, Medistim ASA ranks #66 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 8.7%.
Is Medistim ASA's Return-on-Tangible-Equity too high?
Medistim ASA's current Return-on-Tangible-Equity of 42.10% is 15% above median its 10-year median of 36.57. Over the past 10 years, this metric has ranged from a low of 28.51 to a high of 42.77. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. Medistim ASA's value of 42.10% is 944.7% above this industry median. Based on the distribution chart, Medistim ASA ranks #66 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medistim ASA has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medistim ASA ranks #66 out of 760 companies for Return-on-Tangible-Equity. This places Medistim ASA in the top 9% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.03. Medistim ASA's value of 42.10% is 944.7% above this benchmark. Historically, Medistim ASA's own Return-on-Tangible-Equity has ranged from 28.51 to 42.77 over the past decade. While the company's 10-year median is 36.57 vs. the industry median of 4.03, Medistim ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current Return-on-Tangible-Equity of 42.10% is 944.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medistim ASA and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current Return-on-Tangible-Equity is 42.10%, which is 15% above median its own 10-year median of 36.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (FRA:MD1) is currently considered Modestly Undervalued. The stock's GF Value™ is €23.09, compared to a current price of €19.95 — trading 13.6% below its estimated fair value. The current Return-on-Tangible-Equity is 42.10%, which is 15% above median its 10-year median of 36.57 and 944.7% above the Medical Devices & Instruments industry median of 4.03. Medistim ASA's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medistim ASA (FRA:MD1), the current Return-on-Tangible-Equity is 42.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (FRA:MD1) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued.
The current stock price of €19.95 is trading 13.6% below its estimated GF Value™ of €23.09.
GuruFocus considers Medistim ASA to be Modestly Undervalued.
Key valuation signals for FRA:MD1:
Return-on-Tangible-Equity: 42.10% (15% above median its 10-year median of 36.57)
GF Value™: €23.09 vs. price of €19.95 (13.6% below fair value)
Industry Position: 944.7% above the Medical Devices & Instruments median (#66 of 760)
No single metric tells the full story. See the FRA:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
100GF Score
Get the complete analysis for FRA:MD1
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MD1 has been successfully added to your 
